3TTI

Crystal Structure of JNK3 complexed with CC-930, an orally active anti-fibrotic JNK inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.20 Å
  • R-Value Free: 0.335 
  • R-Value Work: 0.242 
  • R-Value Observed: 0.246 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history


Literature

Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor.

Plantevin Krenitsky, V.Nadolny, L.Delgado, M.Ayala, L.Clareen, S.S.Hilgraf, R.Albers, R.Hegde, S.D'Sidocky, N.Sapienza, J.Wright, J.McCarrick, M.Bahmanyar, S.Chamberlain, P.Delker, S.L.Muir, J.Giegel, D.Xu, L.Celeridad, M.Lachowitzer, J.Bennett, B.Moghaddam, M.Khatsenko, O.Katz, J.Fan, R.Bai, A.Tang, Y.Shirley, M.A.Benish, B.Bodine, T.Blease, K.Raymon, H.Cathers, B.E.Satoh, Y.

(2012) Bioorg Med Chem Lett 22: 1433-1438

  • DOI: 10.1016/j.bmcl.2011.12.027
  • Primary Citation of Related Structures:  
    3TTI

  • PubMed Abstract: 
  • In this Letter we describe the discovery of potent, selective, and orally active aminopurine JNK inhibitors. Improving the physico-chemical properties as well as increasing the potency and selectivity of a subseries with rat plasma exposure, led to the identification of four structurally diverse inhibitors ...

    In this Letter we describe the discovery of potent, selective, and orally active aminopurine JNK inhibitors. Improving the physico-chemical properties as well as increasing the potency and selectivity of a subseries with rat plasma exposure, led to the identification of four structurally diverse inhibitors. Differentiation based on PK profiles in multiple species as well as activity in a chronic efficacy model led to the identification of 1 (CC-930) as a development candidate, which is currently in Phase II clinical trial for IPF.


    Organizational Affiliation

    Celgene Corporation, 4550 Towne Centre Court, San Diego, CA 92121, USA. vplantev@celgene.com



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Mitogen-activated protein kinase 10A464Homo sapiensMutation(s): 0 
Gene Names: JNK3JNK3AMAPK10PRKM10SAPK1B
EC: 2.7.11.24
UniProt & NIH Common Fund Data Resources
Find proteins for P53779 (Homo sapiens)
Explore P53779 
Go to UniProtKB:  P53779
PHAROS:  P53779
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
KBI (Subject of Investigation/LOI)
Query on KBI

Download Ideal Coordinates CCD File 
B [auth A]trans-4-({9-[(3S)-tetrahydrofuran-3-yl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl}amino)cyclohexanol
C21 H23 F3 N6 O2
IBGLGMOPHJQDJB-IHRRRGAJSA-N
 Ligand Interaction
GOL
Query on GOL

Download Ideal Coordinates CCD File 
C [auth A]GLYCEROL
C3 H8 O3
PEDCQBHIVMGVHV-UHFFFAOYSA-N
 Ligand Interaction
Binding Affinity Annotations 
IDSourceBinding Affinity
KBI BindingDB:  3TTI Ki: 44 (nM) from 1 assay(s)
IC50: min: 6, max: 61 (nM) from 2 assay(s)
Binding MOAD:  3TTI IC50: 6 (nM) from 1 assay(s)
PDBBind:  3TTI IC50: 6 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.20 Å
  • R-Value Free: 0.335 
  • R-Value Work: 0.242 
  • R-Value Observed: 0.246 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 52.189α = 90
b = 71.202β = 90
c = 106.813γ = 90
Software Package:
Software NamePurpose
DENZOdata reduction
SCALEPACKdata scaling
MOLREPphasing
REFMACrefinement
PDB_EXTRACTdata extraction
HKL-2000data collection

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment  



Entry History 

Revision History  (Full details and data files)

  • Version 1.0: 2012-02-01
    Type: Initial release
  • Version 1.1: 2012-02-08
    Changes: Database references
  • Version 1.2: 2017-11-08
    Changes: Refinement description